Our findings are a detailed characterization of nasal IgG and IgA responses from a large-scale, placebo-controlled clinical study using an intramuscularly administered COVID-19 vaccine and are strengthened by the size and diversity of the immunogenicity substudy cohort. Here, CD79A is linked to COVID-19.